Skip to content
International Adviser
  • Contact
  • Subscribe
  • Regions
    • United Kingdom
    • Middle East
    • Europe
    • Asia
    • Africa
    • North America
    • Latin America
  • Industry
    • Tax & Regulation
    • Products
    • Life
    • Health & Protection
    • People Moves
    • Companies
    • Offshore Bonds
    • Retirement
    • Technology
    • Platforms
  • Investment
    • Equities
    • Fixed Income
    • Alternatives
    • Multi Asset
    • Property
    • Macro Views
    • Structured Products
    • Emerging Markets
    • Commodities
  • IA 100
  • Best Practice
    • Best Practice News
    • Best Practice Awards
  • Media
    • Video
    • Podcast
  • Directory
  • My IA
    • Events
    • IA Tax Panel
    • IA Intermediary Panel
    • About IA

ANNOUNCEMENT: Read more financial articles on our partner site, click here to read more.

AmMetLife launches Malaysian life plan

By Robbie Lawther, 5 Dec 18

The new solution will include coverage of genomic testing for customers diagnosed with cancer

Malaysia

AmMetLife Insurance Berhad, the strategic partnership between MetLife and AMMB Holdings Berhad, has launched a life plan in Malaysia that includes coverage of genomic testing for customers diagnosed with cancer.

This is part of MetLife’s plan to expand access to new and differentiated health services for customers in Asia to help them better understand and manage their risk of serious illnesses like cancer and determine the best prevention and treatment options.

The HCC BoostUp Rider, attached to the HealthCare Choice Rider, gives customers coverage for a combination of medical benefits including genomic testing for cancer, out-patient dengue treatment, home nursing care, and pre-hospitalisation treatment.

Joyce Au-Yeung, regional head of health for MetLife in Asia, said: “We’re pleased that AmMetLife, is the first insurer to offer a genomic tumour assessment benefit for cancer patients in Malaysia, so they have more information to undertake precision treatment.

“We already offer genomic testing and precision medicine benefits through some of our solutions in China and pharmacogenomics benefits as a value-added service in Korea.”

Specialism

To ensure its services and solutions keep up with medical trends and customers’ evolving needs, MetLife has teamed up with medical experts like Dr Steven Tucker, who specialises in cancer, genomics and precision medicine.

Across Asia, MetLife has launched a combination of holistic insurance solutions and services to help customers better understand how to prevent, diagnose, treat and manage serious illness.

In doing so, the company is focused on the five serious illnesses most relevant to Asians: cancer; cardiovascular disease; diabetes; dementia; and mental health.

Au-Yeung added: “Our ambition is to help customers in Asia increase the number of healthy years they live by providing access to differentiated services to help prevent, diagnose, treat, and manage these conditions.”

AmMetLife offers a range of life assurance and wealth protection solutions distributed through a combination of over 200 AmBank and AmMetLife branded branch offices.

Tags: Malaysia | Metlife

Share this article
Follow by Email
Facebook
fb-share-icon
X (Twitter)
Post on X
LinkedIn
Share

Related Stories

  • Companies

    VIDEO: II’s The Breakfast Briefing EP 2 – Sam Instone, CEO, AES International

    Heather Hopkins

    Industry

    MPS assets surge 32% to £190bn as adviser usage grows

  • Hamid

    Industry

    Former Invesco head launches EM investment platform

    Industry

    Finance firms could face FOS complaints for unsuitable targeted support


NEWSLETTER

Sign Up for International
Adviser Daily Newsletter

subscribe

  • View site map
  • Privacy Policy
  • Terms and Conditions
  • Contact

Published by Money Map Media – part of G&M Media Ltd Copyright (c) 2024.

International Adviser covers the global intermediary market that uses cross-border insurance, investments, banking and pension products on behalf of their high-net-worth clients. No news, articles or content may be reproduced in part or in full without express permission of International Adviser.